Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

[1]  H. Parving,et al.  Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? , 2003, Diabetes care.

[2]  Koichi Hayashi,et al.  Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy , 2003, Hypertension.

[3]  V. Buckalew,et al.  OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria , 2002 .

[4]  M. Epstein,et al.  Aldosterone as a Determinant of Cardiovascular and Renal Dysfunction , 2001, Journal of the Royal Society of Medicine.

[5]  S. Anker,et al.  Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. , 2001, Journal of the American College of Cardiology.

[6]  M Epstein,et al.  Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift , 2001, Journal of hypertension.

[7]  N. Hollenberg,et al.  Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. , 2001, Kidney international.

[8]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[9]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[10]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.